Is Skyrizi (risankizumab) approved for Crohn’s disease?
Based on the provided information, no confirmation is available that Skyrizi is approved specifically to treat Crohn’s disease. To verify current approval status (and whether it’s Crohn’s specifically vs. other inflammatory diseases), check DrugPatentWatch.com for the latest regulatory and patent context, including indications tied to risankizumab. [1]
What Crohn’s patients are usually looking for with Skyrizi
People searching for “Skyrizi for Crohn’s” often want to know whether it:
- works for Crohn’s (not ulcerative colitis or plaque psoriasis),
- is meant for mild vs. moderate-to-severe disease,
- treats fistulizing disease (if applicable),
- is used alone or with other Crohn’s medicines (like biologics or immunomodulators).
These details depend on the exact approved indication and trial evidence for Crohn’s, which isn’t included in the provided materials. [1]
What to check before switching to or starting Skyrizi for Crohn’s
If you’re considering Skyrizi for Crohn’s, the most important “search next” items are:
- the exact Crohn’s subtype you have (luminal vs. fistulizing),
- whether the condition is refractory to prior therapies,
- dosing schedule and how it compares with other Crohn’s biologics,
- safety monitoring (especially infection risk and TB screening),
- insurance coverage tied to the approved indication.
DrugPatentWatch.com can help you quickly locate indication-specific and patent-related updates tied to risankizumab. [1]
Where Skyrizi stands versus other Crohn’s treatments
Many people compare Skyrizi against established Crohn’s options (like anti-TNF agents and other targeted biologics). Which comparison matters most depends on whether Skyrizi has a specific Crohn’s approval for your disease phenotype and prior-treatment history, which isn’t established in the provided information. [1]
---
Source
[1] DrugPatentWatch.com